Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9952
Name acute lymphoblastic leukemia
Definition A acute leukemia that is characterized by over production of lymphoblasts.
Source DiseaseOntology.org
Alt Ids DOID:5600
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CDKN2A mut NRAS act mut Trametinib acute lymphoblastic leukemia resistant detail...
MDM2 over exp TP53 wild-type MX69 acute lymphoblastic leukemia sensitive detail...
KMT2A rearrange Cytarabine + Panobinostat acute lymphoblastic leukemia sensitive detail...
KMT2A rearrange Cytarabine + Mocetinostat acute lymphoblastic leukemia sensitive detail...
KMT2A rearrange Cytarabine + Dacinostat acute lymphoblastic leukemia sensitive detail...
KMT2A rearrange Cytarabine + Romidepsin acute lymphoblastic leukemia sensitive detail...
KMT2A rearrange Romidepsin acute lymphoblastic leukemia decreased response detail...
KMT2A rearrange Cytarabine acute lymphoblastic leukemia sensitive detail...
PTEN loss BGT226 acute lymphoblastic leukemia sensitive detail...
MDM2 over exp TP53 wild-type AQ-101 acute lymphoblastic leukemia sensitive detail...
KMT2A rearrange CYC065 acute lymphoblastic leukemia predicted - sensitive detail...
NRAS G12S IHMT-RAF-128 acute lymphoblastic leukemia sensitive detail...
NRAS A146T IHMT-RAF-128 acute lymphoblastic leukemia sensitive detail...
KMT2A rearrange Fingolimod acute lymphoblastic leukemia sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT00513474 Phase I Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant Completed USA 0
NCT00549848 Phase III Daunorubicin + Pegaspargase + Vincristine Sulfate Cytarabine Mercaptopurine Thioguanine Clofarabine + Cyclophosphamide + Etoposide Methotrexate Dasatinib Doxorubicin Dexamethasone Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Completed USA 0
NCT00550992 Phase I Busulfan Melphalan Mercaptopurine Cytarabine + Etoposide + Mitoxantrone Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine Sulfate Thioguanine Cyclosporine anti-thymocyte globulin Daunorubicin Leucovorin Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia Unknown status USA | ITA | GBR | FRA | DEU | BEL | AUT 2
NCT00679536 Phase Ib/II anti-thymocyte globulin + Busulfan + Fludarabine Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Unknown status USA 0
NCT00777036 Phase II Dasatinib A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 10
NCT00857389 Phase II Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies Completed USA 0
NCT00866281 Phase Ib/II Midostaurin A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia Terminated USA | ITA | FRA 2
NCT00908167 Phase I Clofarabine + Cytarabine + Sorafenib Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies Completed USA 0
NCT00990249 Phase II anti-thymocyte globulin + Busulfan + Clofarabine Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Completed USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01077544 Phase I Nilotinib A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) Completed ITA | GBR | FRA 1
NCT01162551 Phase II Methotrexate + Sirolimus Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma Completed USA 0
NCT01187810 Phase I Fenretinide Cytarabine Methotrexate Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL Terminated USA 0
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Completed USA 1
NCT01256398 Phase II Dexamethasone Dasatinib Tacrolimus Cyclophosphamide + Fludarabine Filgrastim Mercaptopurine + Methotrexate + Vincristine Sulfate Melphalan Cytarabine + Daunorubicin + Etoposide Pegfilgrastim Alemtuzumab Leucovorin Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed USA 0
NCT01266083 Phase II WT1 vaccine Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed USA 0
NCT01319981 Phase II Pegfilgrastim Imatinib Filgrastim Rituximab Doxorubicin Dexamethasone Vincristine Sulfate Cyclophosphamide Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia Completed USA 0
NCT01321346 Phase I Cytarabine Panobinostat A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Completed USA 0
NCT01324180 Phase I Metformin Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Sulfate Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) Completed USA 0
NCT01338987 Phase II Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed USA 0
NCT01371630 Phase Ib/II Inotuzumab ozogamicin Cyclophosphamide + Cytarabine + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Rituximab Cytarabine + Inotuzumab ozogamicin + Methotrexate Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Recruiting USA 0
NCT01424982 Phase II Cytarabine + Methotrexate + Ponatinib Rituximab Ponatinib + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Leucovorin Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT01483690 Phase Ib/II Pegaspargase Methotrexate Dexamethasone Vincristine Sulfate Decitabine Mitoxantrone A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Terminated USA | AUS 0
NCT01491763 FDA approved Cytarabine + Etoposide + Imatinib + Mercaptopurine + Methotrexate Daunorubicin + Imatinib + Prednisone + Vincristine Sulfate Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Unknown status ESP 0
NCT01523977 Phase I Prednisone Everolimus Vincristine Sulfate Doxorubicin Pegaspargase Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL Completed USA 0
NCT01614197 Phase I Etoposide Cyclophosphamide Prednisone Cytarabine Temsirolimus Methotrexate A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma Completed USA | CAN | AUS 0
NCT01620216 Phase II Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients Terminated USA 0
NCT01621477 Phase II Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated USA 0
NCT01634217 Phase I Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Completed USA 0
NCT01658007 Phase I Sirolimus Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma Terminated USA 0
NCT01685411 Phase 0 Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam Busulfan and Cyclophosphamide Followed By ALLO BMT Terminated USA 0
NCT01744223 Phase Ib/II Rimiducid Rivogenlecleucel Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Active, not recruiting USA 0
NCT01746849 Phase II Leuprolide Cyclophosphamide Thiotepa Palifermin Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting USA 0
NCT01769209 Phase II Bortezomib Cytarabine + Methotrexate Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Sulfate Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Completed USA 0
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated USA 1
NCT01841333 Phase II Glasdegib PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant Completed USA 0
NCT01885689 Phase II Clofarabine + Melphalan Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission Active, not recruiting USA 0
NCT01885897 Phase Ib/II ALT-803 IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Completed USA 0
NCT01925131 Phase I Cyclophosphamide + Prednisone + Vincristine Sulfate Inotuzumab ozogamicin S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Completed USA 0
NCT01943682 Phase I CPX-351 Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Completed USA 0
NCT02003222 Phase III Cytarabine Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Pegaspargase Methotrexate + Pegaspargase Cytarabine + Etoposide + Methotrexate Rituximab Blinatumomab Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Active, not recruiting USA | CAN 2
NCT02043587 Phase II Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Sulfate Etoposide Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Terminated USA 0
NCT02071927 Phase I Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Leukemia Completed USA 0
NCT02081378 Phase I Asciminib Asciminib + Imatinib Asciminib + Dasatinib Asciminib + Nilotinib A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL Completed USA | ITA | FRA | ESP | DEU | AUS 4
NCT02083250 Phase I anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia Completed USA 0
NCT02089230 Phase Ib/II Binimetinib MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Terminated USA 0
NCT02091245 Phase I Selinexor Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Active, not recruiting USA 0
NCT02101853 Phase III Blinatumomab Leucovorin + Pegaspargase + Vincristine Sulfate Mercaptopurine + Thioguanine Asparaginase + Cyclophosphamide + Etoposide Cytarabine + Dexamethasone + Methotrexate Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Active, not recruiting USA | CAN | AUS 2
NCT02129062 Phase II Ibrutinib Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Terminated USA 0
NCT02141828 Phase I Pinometostat A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Completed USA | CAN 0
NCT02143635 Phase I Siremadlin Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt Completed USA | FRA | ESP | DEU 4
NCT02146924 Phase I Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT02181478 Phase I Fludarabine Cyclophosphamide Intra-Osseous Co-Transplant of UCB and hMSC Completed USA 0
NCT02199184 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ofatumumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia Completed USA 0
NCT02200380 Phase II Plerixafor CDX-301 A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Terminated USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02212561 Phase Ib/II Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02269579 Phase II CPX-351 Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment Withdrawn USA 0
NCT02319369 Phase I Milademetan Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies Terminated USA 0
NCT02356159 Phase Ib/II Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Recruiting USA 0
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated USA | FRA | ESP | BEL 1
NCT02475707 Phase I MultiTAA-specific T cells Administration of Donor MultiTAA-Specific T Cells for ALL (STELLA) Active, not recruiting USA 0
NCT02484430 Phase II Sapanisertib TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT02487459 Phase I Rivogenlecleucel Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0
NCT02494882 Phase I Dasatinib + Dexamethasone + Ruxolitinib Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older Active, not recruiting USA 0
NCT02518750 Phase II Bortezomib + Dexamethasone + Panobinostat Pegaspargase Mercaptopurine Nelarabine Mitoxantrone Vincristine Sulfate Cyclophosphamide + Etoposide Cytarabine + Methotrexate + Prednisone Clofarabine Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Terminated USA 0
NCT02529813 Phase I Cyclophosphamide + Fludarabine + Tisagenlecleucel CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Completed USA 0
NCT02535806 Phase II Vincristine Sulfate Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults Terminated USA 0
NCT02538926 Phase II Imatinib Rituximab Cyclophosphamide Prednisone Doxorubicin + Etoposide + Vincristine Sulfate Asparaginase Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Withdrawn USA 0
NCT02553460 Phase II Cyclophosphamide Mitoxantrone Dexamethasone Bortezomib Etoposide Vincristine Sulfate Pegaspargase Vorinostat Cytarabine Methotrexate Leucovorin Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I Active, not recruiting USA | CAN 0
NCT02611492 Phase III Mercaptopurine + Methotrexate + Nilotinib Cytarabine + Dexamethasone + Filgrastim + Methotrexate + Nilotinib + Vincristine Sulfate Imatinib A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults (GRAAPH2014) Recruiting FRA 0
NCT02614066 Phase Ib/II axicabtagene ciloleucel A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3) Completed USA | FRA | DEU | CAN 1
NCT02625480 Phase Ib/II axicabtagene ciloleucel A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 4
NCT02629692 Phase Ib/II K0706 Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies Active, not recruiting USA | ITA | GBR | FRA | ESP | BEL 6
NCT02706392 Phase I Cyclophosphamide + Fludarabine + ROR1 CAR-T cells Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies Terminated USA 0
NCT02723994 Phase II Prednisone Dexamethasone + Doxorubicin Leucovorin Mercaptopurine + Thioguanine Asparaginase + Cytarabine Ruxolitinib Cyclophosphamide + Methotrexate + Pegaspargase + Vincristine Sulfate A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Active, not recruiting USA | CAN 1
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT02746952 Phase I UCART19 Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM) Completed USA | GBR | FRA 1
NCT02767934 Phase II Pembrolizumab Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Terminated USA 0
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting USA 0
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Completed USA 0
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Terminated USA 0
NCT02815059 Phase I Dasatinib + Ibrutinib + Prednisone Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone Withdrawn USA 0
NCT02819804 Phase I Dasatinib + Nivolumab Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Terminated USA 0
NCT02861040 Phase I Vincristine Sulfate + Volasertib Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Withdrawn USA 0
NCT02879695 Phase I Blinatumomab + Ipilimumab + Nivolumab Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Active, not recruiting USA 0
NCT02881086 Phase III Rituximab Doxorubicin Cytarabine Mercaptopurine Nelarabine Methotrexate Pegaspargase Cyclophosphamide Vindesine Vincristine Sulfate Daunorubicin Dexamethasone Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Active, not recruiting DEU 0
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT02906371 Phase I Tocilizumab Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome Completed USA 0
NCT02930109 Phase Ib/II Cytarabine + Triciribine A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Unknown status USA 0
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Terminated USA 0
NCT02935543 Phase II CART19 cells CART19 in Patient With ALL Terminated USA 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed USA 0
NCT02997761 Phase II Blinatumomab + Ibrutinib Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03007147 Phase III Pegaspargase Methotrexate Leucovorin Cytarabine Mercaptopurine Thioguanine Vincristine Sulfate Cyclophosphamide Imatinib Ifosfamide Dexrazoxane Daunorubicin Dexamethasone Methylprednisolone Etoposide Prednisolone Doxorubicin Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Recruiting USA | ITA | FRA | DEU | CAN | BEL | AUT | AUS 11
NCT03020030 Phase III Nelarabine Dexrazoxane Asparaginase Vincristine Sulfate Cyclophosphamide Cytarabine Mercaptopurine Pegaspargase Methotrexate Etoposide Doxorubicin Dexamethasone Prednisone Dasatinib Leucovorin Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Active, not recruiting USA | CAN 0
NCT03023046 Phase II Rituximab Doxorubicin Etoposide Imatinib Dasatinib Cyclophosphamide Prednisone Vincristine Sulfate Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed USA 0
NCT03056339 Phase Ib/II Cyclophosphamide + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies Completed USA 0
NCT03069469 Phase I Vimseltinib Study of DCC-3014 in Patients With Advanced Malignancies Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 2
NCT03071276 Phase II Cytarabine + Fludarabine + Methotrexate + Prednisone + Selinexor Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia Terminated USA 0
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03094611 Phase II Inotuzumab ozogamicin Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia Terminated USA 0
NCT03103971 Phase I Cyclophosphamide + Fludarabine + HuJCAR014 huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT03104491 Phase Ib/II Inotuzumab ozogamicin Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia Recruiting USA 0
NCT03110354 Phase I DS-3201b DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) Terminated USA 0
NCT03117751 Phase II Cyclophosphamide Vincristine Sulfate Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Active, not recruiting USA | AUS 0
NCT03128034 Phase Ib/II Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Suspended USA 0
NCT03132454 Phase I Decitabine + Palbociclib Dexamethasone + Palbociclib Palbociclib Palbociclib + Sorafenib Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias Recruiting USA 0
NCT03147612 Phase II Pegfilgrastim Blinatumomab Vincristine Sulfate Rituximab Filgrastim Ponatinib Cyclophosphamide Methotrexate Cytarabine Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT03150693 Phase III Rituximab Doxorubicin Mercaptopurine Methotrexate Cyclophosphamide + Cytarabine Thioguanine Allopurinol Daunorubicin Dexamethasone Vincristine Sulfate Inotuzumab ozogamicin Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia Suspended USA | CAN 0
NCT03160079 Phase Ib/II Blinatumomab + Pembrolizumab Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts Active, not recruiting USA 0
NCT03181126 Phase I Navitoclax + Venetoclax A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia Completed USA | AUS 0
NCT03241940 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Recruiting USA 0
NCT03263572 Phase II Blinatumomab + Cytarabine + Methotrexate + Ponatinib Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed GBR | DEU 1
NCT03267186 Phase II Ibrutinib Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Completed USA 0
NCT03286114 Phase I Pembrolizumab Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab Terminated USA 0
NCT03319901 Phase I Cytarabine Mercaptopurine Methotrexate Cyclophosphamide Venetoclax Doxorubicin Etoposide Vincristine Sulfate Venetoclax and Chemotherapy In ALL Recruiting USA 0
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Suspended USA 0
NCT03349281 Phase I Dexamethasone + Doxorubicin + MLN4924 + Pegaspargase + Vincristine Sulfate Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia Completed USA 0
NCT03386513 Phase Ib/II IMGN632 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 0
NCT03414450 Phase I Dasatinib + ETC-1907206 Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies Withdrawn USA 1
NCT03460522 Phase II Inotuzumab ozogamicin Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL Recruiting DEU 0
NCT03472573 Phase I Dexamethasone + Palbociclib Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Completed USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT03483324 Phase I AB-110 Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Completed USA 0
NCT03488225 Phase II Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Leucovorin + Methotrexate Inotuzumab ozogamicin Ofatumumab Rituximab Cytarabine + Doxorubicin + Methotrexate + Vincristine Sulfate Pegfilgrastim Cyclophosphamide + Dexamethasone + Mesna Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia Terminated USA 0
NCT03504644 Phase Ib/II Venetoclax + Vincristine Sulfate Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03512405 Phase Ib/II Blinatumomab + Pembrolizumab Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03515200 Phase I Cytarabine + Dexamethasone + Methotrexate Bortezomib + Dasatinib + Dexamethasone + Doxorubicin + Palbociclib Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia Terminated USA 0
NCT03571321 Phase I Pegaspargase Methotrexate Cytarabine Mercaptopurine Thioguanine Ruxolitinib Cyclophosphamide Dexamethasone Vincristine Sulfate Rituximab Doxorubicin Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03575325 Phase II CPX-351 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Completed USA 0
NCT03576547 Phase Ib/II Dexamethasone + Ponatinib + Rituximab + Venetoclax Dexamethasone + Ponatinib + Venetoclax Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Active, not recruiting USA 0
NCT03579888 Phase I CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine CD19-Specific T Cells Post AlloSCT Terminated USA 0
NCT03589326 Phase III Cytarabine + Methotrexate + Ponatinib Dexamethasone + Ponatinib + Vincristine Sulfate Ponatinib + Prednisone + Vincristine Sulfate Dexamethasone + Imatinib + Vincristine Sulfate Cytarabine + Imatinib + Methotrexate Imatinib + Prednisone + Vincristine Sulfate A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Active, not recruiting USA | ITA | FRA | ESP | CAN | AUT | AUS 13
NCT03592576 Expanded access Navitoclax Expanded Access to Navitoclax Available 0
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Recruiting USA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03698552 Phase Ib/II ADCT-602 ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03739606 Phase II Flotetuzumab Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Withdrawn 0
NCT03739814 Phase II Blinatumomab + Inotuzumab ozogamicin Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03740334 Phase I Dexamethasone + Ribociclib Dexamethasone + Everolimus + Ribociclib Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL Active, not recruiting USA 0
NCT03751709 Phase I Blinatumomab Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL Active, not recruiting USA 0
NCT03807063 Phase I Rimiducid Rivogenlecleucel Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03808610 Phase Ib/II Cyclophosphamide + Dexamethasone + Venetoclax + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Rituximab + Venetoclax + Vincristine Sulfate Cytarabine + Methotrexate + Venetoclax Cytarabine + Methotrexate + Rituximab + Venetoclax Nelarabine + Pegaspargase Prednisone + Venetoclax + Vincristine Sulfate Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Recruiting USA 0
NCT03821610 Phase II Alemtuzumab + Cyclophosphamide + Mesna Alemtuzumab + Fludarabine + Melphalan A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) (ALL-RIC) Active, not recruiting GBR 0
NCT03826992 Phase I CPX-351 + Venetoclax Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Recruiting USA 0
NCT03829540 Phase I CD4CAR CD4CAR for CD4+ Leukemia and Lymphoma Recruiting USA 0
NCT03851081 Phase Ib/II Inotuzumab ozogamicin + Vincristine sulfate liposome Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Withdrawn USA 0
NCT03856216 Phase II Methotrexate Filgrastim + Methotrexate + Rituximab Rituximab Bendamustine + Fludarabine + Inotuzumab ozogamicin + Tacrolimus Filgrastim + Methotrexate Inotuzumab ozogamicin Fludarabine + Inotuzumab ozogamicin + Melphalan + Tacrolimus anti-thymocyte globulin Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation Recruiting USA 0
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Completed USA 0
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Active, not recruiting CAN 0
NCT03914625 Phase III Cytarabine + Leucovorin + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Dexamethasone + Methotrexate Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Blinatumomab + Methotrexate Mercaptopurine + Methotrexate + Vincristine Sulfate Blinatumomab + Dexamethasone + Leucovorin + Methotrexate Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Leucovorin + Methotrexate Blinatumomab + Dexamethasone + Leucovorin Mercaptopurine + Methotrexate + Prednisolone + Vincristine Sulfate Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Leucovorin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Leucovorin + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Leucovorin + Methotrexate + Vincristine Sulfate Methotrexate + Vincristine Sulfate Dexamethasone + Mercaptopurine + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Cytarabine + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Dexamethasone + Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma Recruiting USA | CAN | AUS 2
NCT03934372 Phase Ib/II Ponatinib Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors Recruiting ITA | GBR | FRA | ESP | DEU | BEL 3
NCT03938987 Phase Ib/II Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) Recruiting CAN 0
NCT03991884 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Inotuzumab ozogamicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Inotuzumab ozogamicin + Prednisone + Vincristine Sulfate Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Completed USA 0
NCT04065399 Phase Ib/II Revumenib A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 3
NCT04088864 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Active, not recruiting USA 0
NCT04088890 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Active, not recruiting USA 0
NCT04103879 Phase II ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia Active, not recruiting USA 1
NCT04145531 Phase II JZP-458 An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Completed USA | CAN 0
NCT04225676 Phase II Tisagenlecleucel Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) Terminated USA 0
NCT04323657 Phase Ib/II Cyclophosphamide + Fludarabine TC-110 T-cells TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Completed USA 0
NCT04329325 Phase II Dasatinib + Dexamethasone + Methotrexate Blinatumomab + Dasatinib + Methotrexate Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Active, not recruiting USA 0
NCT04475731 Phase II Ponatinib Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse Recruiting ITA 0
NCT04501614 Phase Ib/II Ponatinib A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Active, not recruiting USA | ITA | GBR | FRA | ESP | AUS 9
NCT04524455 Phase I Dexamethasone AMG 404 + Blinatumomab A Study of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Acute Lymphoblastic Leukemia (ALL) Completed USA | ITA | GBR | FRA | ESP | DEU | AUT | AUS 1
NCT04530565 Phase III Cyclophosphamide + Dasatinib + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Dexamethasone + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Prednisone Dasatinib Ponatinib Blinatumomab + Dexamethasone + Methotrexate + Ponatinib + Prednisone Blinatumomab + Dasatinib + Dexamethasone + Methotrexate + Prednisone Ponatinib + Prednisone Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Mesna + Methotrexate + Vincristine Sulfate Cytarabine + Methotrexate + Ponatinib Cytarabine + Dasatinib + Methotrexate Cyclophosphamide + Dexamethasone + Doxorubicin + Ponatinib + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Ponatinib + Vincristine Sulfate Dasatinib + Prednisone Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Recruiting USA 2
NCT04684563 Phase I HuCART19-IL18 huCART19-IL18 in CD19+ Cancers Recruiting USA 0
NCT04722848 Phase III Blinatumomab + Ponatinib Imatinib Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL Recruiting ITA 0
NCT04730349 Phase Ib/II Nivolumab + NKTR-214 A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) Terminated USA | ITA | FRA | ESP | DEU | AUS 0
NCT04752163 Phase Ib/II Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed USA 0
NCT04778579 Phase II ARI-0001 Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy (CART19-BE-02) Active, not recruiting ESP 0
NCT04845035 Phase II Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate + Ponatinib Mercaptopurine + Methotrexate Asparaginase + Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Doxorubicin + Methotrexate + Thioguanine + Vincristine Sulfate Leucovorin + Mercaptopurine + Methotrexate Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin + Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Asparaginase + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Thioguanine + Vincristine Sulfate Mercaptopurine + Methotrexate + Ponatinib Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Withdrawn USA 0
NCT04865419 Phase Ib/II AZD0466 + Voriconazole AZD0466 Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies Terminated USA | ITA | FRA | DEU | AUS 1
NCT04872478 Phase I MRX-2843 Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL Recruiting USA 0
NCT04877522 FDA approved Asciminib Bosutinib Dasatinib Nilotinib Asciminib + Imatinib Asciminib Roll-over Study Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 17
NCT04988555 Phase Ib/II DSP-5336 A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation Recruiting USA 1
NCT04996160 Phase I Bortezomib + Dexamethasone + Doxorubicin + Palbociclib Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) Recruiting USA 0
NCT05044039 Phase I Duvelisib Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy Recruiting USA 0
NCT05192889 Phase Ib/II Dexamethasone + Pegaspargase + Vincristine Sulfate Blinatumomab + Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Venetoclax Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Hydrocortisone + Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Methotrexate + Navitoclax + Pegaspargase + Venetoclax Dasatinib + Dexamethasone + Pegaspargase + Vincristine Sulfate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dexamethasone + Hydrocortisone + Leucovorin + Methotrexate + Navitoclax + Pegaspargase + Venetoclax + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Etoposide + Hydrocortisone + Leucovorin + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Navitoclax + Pegaspargase + Venetoclax Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Methotrexate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Leucovorin + Methotrexate + Navitoclax + Pegaspargase + Venetoclax + Vincristine Sulfate Blinatumomab + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Methotrexate + Venetoclax Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax Recruiting USA 0
NCT05215405 Expanded access Navitoclax + Venetoclax Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL Available USA 0
NCT05306301 Phase II Ponatinib Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Recruiting ITA 0
NCT05326516 Phase I Revumenib A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia Active, not recruiting USA | CAN 0
NCT05386576 Phase I Venetoclax A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Recruiting USA 0
NCT05397496 Phase I PIT565 Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies Recruiting USA | ITA | FRA | ESP | BEL 3
NCT05400122 Phase I Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Suspended USA 0
NCT05476770 Phase I Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Recruiting USA | AUS 0
NCT05480449 Phase Ib/II huCART19 Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) Recruiting USA 0
NCT05487651 Phase I KUR-502 Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2) Recruiting USA 0
NCT05658640 Phase Ib/II Cyclophosphamide + Cytarabine + Dexamethasone + Trametinib HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D) Not yet recruiting 1
NCT05707273 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission Recruiting USA 0
NCT05740449 Phase Ib/II Decitabine + Navitoclax + Venetoclax HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A) Not yet recruiting 1
NCT05751044 Phase Ib/II Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Venetoclax HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B) Not yet recruiting 1
NCT05756322 Phase Ib/II LBS-007 The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias Recruiting AUS 1
NCT05761171 Phase II Cytarabine + Fludarabine Pegaspargase + Prednisone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisone + Vincristine Sulfate Revumenib Cytarabine + Hydrocortisone + Methotrexate Pegaspargase + Prednisolone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisolone + Vincristine Sulfate A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Active, not recruiting USA 0
NCT05775406 Phase I KT-253 Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Recruiting USA 0
NCT05848687 Phase Ib/II Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Recruiting USA 0
NCT05918692 Phase I BMF-500 A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Recruiting USA 0
NCT06061094 Phase II Blinatumomab + Ponatinib Imatinib Blinatumomab + Imatinib Ponatinib Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT (GMALL-EVOLVE) Recruiting DEU 0
NCT06208735 Phase I CLIC-2201 CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies Not yet recruiting CAN 0
NCT06227026 Phase I Anti-CD19 CAR-T cells Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY) Recruiting USA 0
NCT06287944 Phase I Melphalan Fludarabine Sirolimus 225Ac-DOTA-Daratumumab Tacrolimus 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome Not yet recruiting USA 0